Research Summary: Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is a low-grade B-cell malignancy. Since the introduction of targeted therapies directed at Bruton tyrosine kinase (BTK) and the B-cell lymphoma 2 (BCL2) protein, CLL outcomes have improved. Patients with CLL were historically treated with chemo-immunotherapy...
Read MoreResearch Summary: Traditionally, the gold standard treatment option for patients with cisplatin-eligible clinically localized muscle invasive bladder cancer (MIBC) has been cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) with urinary diversion. However, more recently, immune checkpoint inhibitors (ICIs) have been introduced as an...
Read MoreResearch Summary: For patients with bacillus Calmette-Guérin (BCG)–naïve, high-risk non-muscle invasive bladder cancer (NMIBC), the standard of care is transurethral resection of bladder tumor (TURBT) followed by BCG therapy. However, early recurrence rates remain high, and patients with early recurrence and high-risk NMIBC face an...
Read MoreResearch Summary: Many estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) breast tumors develop resistance to aromatase inhibitors (AIs) alone or in combination with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. However, the capacity for selective ER degraders (SERDs) to induce ER alpha degradation...
Read MoreLearn how cilta-cel improved survival, disease control, and symptom outcomes versus standard care in lenalidomide-refractory multiple myeloma.
Read MoreExplore how adding durvalumab to chemotherapy may improve survival and offer a cost-effective treatment option for muscle invasive bladder cancer.
Read MoreLearn how consolidation durvalumab after sequential chemoradiotherapy demonstrated favorable long-term survival and a manageable safety profile in unresectable stage III NSCLC in the PACIFIC-6 trial.
Read MoreResearch Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung cancer (NSCLC), and current first-line standards based on immune checkpoint inhibitors (ICIs), with or without chemotherapy, yield suboptimal long-term outcomes. Olomorasib is an orally bioavailable, highly selective KRAS G12C inhibitor...
Read More
Eric, his wife and care partner Sally, and Eric’s oncologist,...
Read More
Dr. Samuel Klempner reviews key data from the MATTERHORN trial,...
Read More
Dr. Galsky discusses unmet needs for patients with high-risk non-muscle...
Read More
Dr. Gautam Jayram highlights how adding durvalumab to standard gemcitabine–cisplatin...
Read More
Learn how durvalumab plus gemcitabine/cisplatin improved long-term survival in the...
Read More
Stephanie Gregory, MS, FNP-C, BMTCN, and Jacob Bartlett, PA-C, from...
Read More
Patricia Mangan, CRNP, talked about the importance of Carvykti moving...
Read More
Dr. Brigle discusses a few pearls for clinicians to consider...
Read More
Monica White, RN, discusses her session focusing on the bone...
Read More
Daniela Molena, MD, of the Memorial Sloan Kettering Cancer Center,...
Read More
Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, and Miriam Hobbs,...
Read More
Learn how shared decision-making helps patients and care teams choose...
Read More©2026 Oncology Matrix. All Rights Reserved.
